Rapidly define potential QTc and QRS risk

Data Card

Enhance the predictive accuracy of cardiac safety assessments to ensure safer drug development and reduce the likelihood of late-stage failures due to cardiac toxicity

Evaluating multiple endpoints including APD20/50/90 (action potential duration at different repolarisation stages), rise time, beat rate, and triangulation is crucial for assessing cardiovascular risk in drug discovery. It provides a comprehensive understanding of a compound's effects on cardiac electrophysiology. These endpoints collectively help identify proarrhythmic risks by detecting subtle changes in ion channel function that may not be apparent from a single parameter. APD20/50/90 measurements assess repolarisation dynamics, crucial for detecting the risk of QTc prolongation risks and early afterdepolarizations (EADs. Rise time reflects sodium channel activity and depolarization efficiency, while beat rate monitors drug-induced chronotropic effects. Triangulation (the difference between APD90 and APD30) is a key indicator of repolarization instability linked to Torsades de Pointes (TdP) risk.

By analysing multiple endpoints simultaneously, researchers can enhance the predictive accuracy of cardiac safety assessments, ensuring safer drug development and reducing the likelihood of late-stage failures due to cardiac toxicity.

Contact us for a quote or discussion

Recommended Publications

Latest Publications

Nav1.5 late current in WT and Nav1.5-ΔKPQ mutant channels: an automated patch clamp LQT3 electrophysiological assay comparison

The cardiac late Na+ current (late INa) generates persistent inward currents throughout the plateau phase of the ventricular action potential and is an important determinant of repolarisation rate, EADs and arrythmia risk¹. As inhibition of late INa can offset drug effects on hERG and other repolarising K⁺conductances, it is one of the key cardiac channels in the Comprehensive in vitro Pro-arrythmia Assay (CiPA) panel being developed by the FDA to improve human clinical arrythmia risk assessment²̛ ³.

Development of an impedance-based screening assay for cardiac safety and cardiotoxicity detection in stem cell-derived cardiomyocytes

Cardiac toxicity remains the leading cause of new drug safety side-effects. Current preclinical cardiac safety assays rely on in vitro cell-based ion channel assays and ex vivo and in vivo animal models⁽¹⁾. These assays provide an indication of acute risk but they do not always predict the effect of chronic compound exposure, as recently seen with oncology drugs. Therefore, new assays are required to characterise chronic structural and functional effects in human cells earlier in drug discovery. Impedance-based technology can provide more accurate chronic cardiotoxicity measurements in an efficient manner using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

View All

Bridging resource gaps in preclinical ion channel discovery

Nav1.5 late current in WT and Nav1.5-ΔKPQ mutant channels: an automated patch clamp LQT3 electrophysiological assay comparison

View All